Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives ...

Genfit (NASDAQ:GNFT) saw its stock decline 9% following the company’s announcement to discontinue its VS-01 therapy for Acute-on-Chronic Liver Failure (ACLF). The decision came after a safety incident ...

Genfit SA is discontinuing its VS-01 program in acute-on-chronic liver failure (ACLF), and has decided to reprioritize development of VS-01 for urea cycle disorder.

Genfit has stopped development of VS-01 in acute-on-chronic liver failure (ACLF) after a patient suffered a serious adverse event in a phase 2 trial. The French drugmaker acquired VS-01 when it bought ...